{
    "pubmed_id": 35040666,
    "study_identifier": "PMID35040666_study-01",
    "study_name": "Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity",
    "publication_title": "Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity",
    "study_objective": "To study the biology of afucosylated IgG immune complexes",
    "study_description": "A damaging inflammatory response is implicated in the pathogenesis of severe coronavirus disease 2019 (COVID-19), but mechanisms contributing to this response are unclear. In two prospective cohorts, early non-neutralizing, afucosylated immunoglobulin G (IgG) antibodies specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were associated with progression from mild to more severe COVID-19. To study the biology of afucosylated IgG immune complexes, we developed an in vivo model that revealed that human IgG-Fc-gamma receptor (Fc\u03b3R) interactions could regulate inflammation in the lung. Afucosylated IgG immune complexes isolated from patients with COVID-19 induced inflammatory cytokine production and robust infiltration of the lung by immune cells. In contrast to the antibody structures that were associated with disease progression, antibodies that were elicited by messenger RNA SARS-CoV-2 vaccines were highly fucosylated and enriched in sialylation, both modifications that reduce the inflammatory potential of IgG. Vaccine-elicited IgG did not promote an inflammatory lung response. These results show that human IgG-Fc\u03b3R interactions regulate inflammation in the lung and define distinct lung activities mediated by the IgG that are associated with protection against, or progression to, severe COVID-19.",
    "primary_institution_name": "Stanford University",
    "study_personnel": [
        {
            "personnel_id": "PMID35040666_personnel-01",
            "honorific": "",
            "last_name": "Scott",
            "first_name": "Boyd",
            "suffixes": "",
            "organization": "Stanford University",
            "orchid_id": "",
            "email": "sboyd1@stanford.edu",
            "seronet_title_in_study": "SeroNet Principal Investigator",
            "role_in_study": "Investigator",
            "site_name": "Stanford University"
        },
        {
            "personnel_id": "PMID35040666_personnel-02",
            "honorific": "",
            "last_name": "Taia",
            "first_name": "Wang",
            "suffixes": "",
            "organization": "Stanford University",
            "orchid_id": "",
            "email": "taiawang@stanford.edu",
            "seronet_title_in_study": "Corresponding Author",
            "role_in_study": "Corresponding Author",
            "site_name": "Stanford University"
        },
        {
            "personnel_id": "PMID35040666_personnel-03",
            "honorific": "",
            "last_name": "Davis",
            "first_name": "Mark",
            "suffixes": "",
            "organization": "Stanford University",
            "orchid_id": "",
            "email": "mmdavis@stanford.edu",
            "seronet_title_in_study": "SeroNet Investigator",
            "role_in_study": "Investigator",
            "site_name": "Stanford University"
        }
    ],
    "study_file": [
        {
            "study_file_name": "scitranslmed.abm7853_sm.pdf",
            "study_file_description": "Supplemental data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "scitranslmed.abm7853_data_file_s1.xlsx",
            "study_file_description": "Supplemental data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "PMID35040666_v1.2.3.xlsm",
            "study_file_description": "Completed curation of the study into SeroNet Registry Template which includes SeroNet Study Descriptors.",
            "study_file_type": "Study Summary Description"
        }
    ],
    "study_link": [],
    "research_focus": "Immune Response",
    "study_type": "Clinical Research",
    "keyword": [
        "Antibodies Neutralizing",
        "Antibodies Viral",
        "Antibody Formation",
        "COVID-19 Vaccines",
        "COVID-19",
        "Humans",
        "Prospective Studies",
        "SARS-CoV-2 Spike Glycoprotein Coronavirus"
    ],
    "clinical_study_design": "Prospective Cohort",
    "in_silico_model_type": "",
    "protocol": {
        "protocol_id": "PMID35040666_protocol-01",
        "protocol_file_name": "PMID35040666_protocol-01.txt",
        "protocol_name": "PMID35040666_protocol-01",
        "protocol_description": "Study Protocol",
        "protocol_type": "Study Protocol"
    },
    "reported_health_condition": [
        "Covid-19"
    ],
    "sars_cov_2_vaccine_type": [
        "Pfizer-BioNTech"
    ],
    "clinical_outcome_measure": "",
    "enrollment_start_date": "",
    "enrollment_end_date": "",
    "number_of_study_subjects": 259,
    "age_unit": "Years",
    "minimum_age": 18,
    "maximum_age": 98,
    "study_human_cohort": [
        {
            "arm_id": "PMID35040666_human_subject-01",
            "arm_name": "Stanford Lambda cohort (Cohort 1)",
            "study_population_description": "Adults who tested positive for SARS-CoV-2 and received subcutaneous injection of Lambda or saline placebo (n= 109)",
            "arm_type": "Observational",
            "ethnicity": [
                "Hispanic or Latino",
                "Not Specified"
            ],
            "race": [
                "White",
                "Asian",
                "Other"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Female",
                "Male"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: California"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [
                "Post-acute sequelae of COVID-19 (>= 4 weeks)"
            ],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Infected"
            ],
            "sars_cov_2_vaccine_type": [
                "n/a"
            ],
            "covid_19_disease_severity": [
                "Mild"
            ],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID35040666_human_subject-02",
            "arm_name": "Stanford Favipiravir Cohort (Cohort 2)",
            "study_population_description": "Adults who tested positive for SARS-CoV-2 and mildly symptomatic with no evidence of respiratory distress. Participants were randomized to receive Favipiravir or placebo. (n=149)",
            "arm_type": "Observational",
            "ethnicity": [
                "Hispanic or Latino",
                "Not Specified"
            ],
            "race": [
                "White",
                "Asian",
                "Other"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Female",
                "Male"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: California"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [
                "Post-acute sequelae of COVID-19 (>= 4 weeks)"
            ],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Infected"
            ],
            "sars_cov_2_vaccine_type": [
                "n/a"
            ],
            "covid_19_disease_severity": [
                "Mild"
            ],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID35040666_human_subject-03",
            "arm_name": "Mount Sinai cohort",
            "study_population_description": "Hospitalized patients from Mount Sinai cohort (N= 52)",
            "arm_type": "Observational",
            "ethnicity": [
                "Hispanic or Latino",
                "Not Specified"
            ],
            "race": [
                "White",
                "Asian",
                "Other"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Female",
                "Male"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: California"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [
                "Post-acute sequelae of COVID-19 (>= 4 weeks)"
            ],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Infected"
            ],
            "sars_cov_2_vaccine_type": [
                "n/a"
            ],
            "covid_19_disease_severity": [
                "Severe"
            ],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID35040666_human_subject-04",
            "arm_name": "Pfizer BNT162b2 mRNA vaccine group",
            "study_population_description": "Healthy adults who received Pfizer BNT162b2 SARS-CoV-2 mRNA vaccine (n=29)",
            "arm_type": "Healthy Control",
            "ethnicity": [
                "Hispanic or Latino",
                "Not Specified"
            ],
            "race": [
                "White I Asian I Black or African American I Other"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Female",
                "Male"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: California"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [
                "na"
            ],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaccinated"
            ],
            "sars_cov_2_vaccine_type": [
                "Pfizer BioNTech COVID-19 vaccine ; VO:0004987"
            ],
            "covid_19_disease_severity": [
                "n/a"
            ],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        }
    ],
    "study_model_cohort": [
        {
            "arm_id": "PMID35040666_organism_subject-05",
            "arm_name": "Mice (Group A)",
            "study_population_description": "Group A 8 to 12 weeks mice treated with afucosylated ICs (n=3)",
            "arm_type": "Experimental Arm",
            "genus_and_species": [
                "Mus musculus"
            ],
            "biosample_type": [
                "Animal"
            ],
            "strain_characteristics": [],
            "sex_at_birth": [
                "Female",
                "Male"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "study_location": [
                "US: California"
            ],
            "sars_cov_2_history": [],
            "sars_cov_2_vaccine_type": [
                "n/a"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptons": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID35040666_organism_subject-06",
            "arm_name": "Mice (Group B)",
            "study_population_description": "Group B 8 to 12 weeks mice treated with normally fucosylated ICs (n=3)",
            "arm_type": "Experimental Arm",
            "genus_and_species": [
                "Mus musculus"
            ],
            "biosample_type": [
                "Animal"
            ],
            "strain_characteristics": [],
            "sex_at_birth": [
                "Female",
                "Male"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "study_location": [
                "US: California"
            ],
            "sars_cov_2_history": [],
            "sars_cov_2_vaccine_type": [
                "n/a"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptons": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID35040666_organism_subject-07",
            "arm_name": "Mice (Group C)",
            "study_population_description": "Group C 8 to 12 weeks mice treated vaccine-induced ICs (n=4)",
            "arm_type": "Experimental Arm",
            "genus_and_species": [
                "Mus musculus"
            ],
            "biosample_type": [
                "Animal"
            ],
            "strain_characteristics": [],
            "sex_at_birth": [
                "Female",
                "Male"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "study_location": [
                "US: California"
            ],
            "sars_cov_2_history": [],
            "sars_cov_2_vaccine_type": [
                "n/a"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptons": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID35040666_organism_subject-08",
            "arm_name": "Mice (Group D)",
            "study_population_description": "Group D 8 to 12 weeks mice treated with spike protein alone (n=4)",
            "arm_type": "Experimental Arm",
            "genus_and_species": [
                "Mus musculus"
            ],
            "biosample_type": [
                "Animal"
            ],
            "strain_characteristics": [],
            "sex_at_birth": [
                "Female",
                "Male"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "study_location": [
                "US: California"
            ],
            "sars_cov_2_history": [],
            "sars_cov_2_vaccine_type": [
                "n/a"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptons": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID35040666_organism_subject-09",
            "arm_name": "Mice (Group E)",
            "study_population_description": "Group E 8 to 12 weeks mice  were pretreated with chemokine-neutralizing mAbs  (n=4)",
            "arm_type": "Experimental Arm",
            "genus_and_species": [
                "Mus musculus"
            ],
            "biosample_type": [
                "Animal"
            ],
            "strain_characteristics": [],
            "sex_at_birth": [
                "Female",
                "Male"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "study_location": [
                "US: California"
            ],
            "sars_cov_2_history": [],
            "sars_cov_2_vaccine_type": [
                "n/a"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptons": [],
            "covid_19_complications": []
        }
    ],
    "planned_visit": [
        {
            "visit_id": "PMID35040666_visit-01",
            "visit_name": "Peripheral blood collected from Lambda cohort 1 on enrollment day",
            "visit_order_number": 1,
            "visit_min_start_day": 0,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35040666_visit-02",
            "visit_name": "Peripheral blood collected from Lambda cohort 1. Oropharyngeal swabs, blood samples collected from Favipiravir Cohort",
            "visit_order_number": 2,
            "visit_min_start_day": 5,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35040666_visit-03",
            "visit_name": "Peripheral blood collected from Lambda 1, vaccinated, Favipiravir Cohort. Favipiravir Cohort's Oropharyngeal swabs collected.",
            "visit_order_number": 3,
            "visit_min_start_day": 28,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35040666_visit-04",
            "visit_name": "Peripheral blood collected from Stanford Lambda cohort 1 at 4 months",
            "visit_order_number": 4,
            "visit_min_start_day": 120,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35040666_visit-05",
            "visit_name": "Peripheral blood collected from Stanford Lambda cohort 1 at 7 months",
            "visit_order_number": 5,
            "visit_min_start_day": 210,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35040666_visit-06",
            "visit_name": "Peripheral blood collected from Stanford Lambda cohort 1 at 10 months",
            "visit_order_number": 6,
            "visit_min_start_day": 300,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35040666_visit-07",
            "visit_name": "Oropharyngeal swabs and blood samples were collected from Stanford Favipiravir Cohort on day 1",
            "visit_order_number": 7,
            "visit_min_start_day": 1,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35040666_visit-08",
            "visit_name": "Oropharyngeal swabs and blood samples were collected from Stanford Favipiravir Cohort on day 10",
            "visit_order_number": 8,
            "visit_min_start_day": 10,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35040666_visit-09",
            "visit_name": "Oropharyngeal swabs and blood samples were collected from Stanford Favipiravir Cohort on day 21",
            "visit_order_number": 9,
            "visit_min_start_day": 21,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        }
    ],
    "experiment": [
        {
            "arm_id": [
                "PMID35040666_human_subject-01",
                "PMID35040666_human_subject-02",
                "PMID35040666_human_subject-03 IPMID35040666_human_subject-04"
            ],
            "associated_first_planned_visit_id": [
                "PMID35040666_visit-01",
                "PMID35040666_visit-02",
                "PMID35040666_visit-03",
                "PMID35040666_visit-04",
                "PMID35040666_visit-05",
                "PMID35040666_visit-06",
                "PMID35040666_visit-07",
                "PMID35040666_visit-08",
                "PMID35040666_visit-09"
            ],
            "assay_type": "Neutralizing Antibody Titer Assay",
            "experiment_name": "Neutralization assays",
            "experiment_results_file_name": "scitranslmed.abm7853_data_file_s1.xlsx",
            "biospecimen_type": [
                "Plasma"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination I Post-symptom onset"
            ],
            "sars_cov_2_antigen": [
                "n/a"
            ],
            "assay_use": "",
            "manufacture": "components from multiple manufacturers",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "Other"
            ],
            "reporting_units": "",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID35040666_human_subject-01",
                "PMID35040666_human_subject-02",
                "PMID35040666_human_subject-03 IPMID35040666_human_subject-04"
            ],
            "associated_first_planned_visit_id": [
                "PMID35040666_visit-01",
                "PMID35040666_visit-02",
                "PMID35040666_visit-03",
                "PMID35040666_visit-04",
                "PMID35040666_visit-05",
                "PMID35040666_visit-06",
                "PMID35040666_visit-07",
                "PMID35040666_visit-08",
                "PMID35040666_visit-09"
            ],
            "assay_type": "ELISA",
            "experiment_name": "ELISA",
            "experiment_results_file_name": "scitranslmed.abm7853_data_file_s1.xlsx",
            "biospecimen_type": [
                "Serum"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination I Post-symptom onset"
            ],
            "sars_cov_2_antigen": [],
            "assay_use": "",
            "manufacture": "components from multiple manufacturers",
            "catalog_number": "",
            "virus_target": [],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "",
            "assay_reporting_format": ""
        },
        {
            "arm_id": [
                "PMID35040666_human_subject-01",
                "PMID35040666_human_subject-02",
                "PMID35040666_human_subject-03 IPMID35040666_human_subject-04",
                "PMID35040666_organism_subject-05",
                "PMID35040666_organism_subject-06",
                "PMID35040666_organism_subject-07",
                "PMID35040666_organism_subject-08",
                "PMID35040666_organism_subject-09"
            ],
            "associated_first_planned_visit_id": [
                "PMID35040666_visit-01",
                "PMID35040666_visit-02",
                "PMID35040666_visit-03",
                "PMID35040666_visit-04",
                "PMID35040666_visit-05",
                "PMID35040666_visit-06",
                "PMID35040666_visit-07",
                "PMID35040666_visit-08",
                "PMID35040666_visit-09"
            ],
            "assay_type": "Flow Cytometry",
            "experiment_name": "Fc gamma R quantification",
            "experiment_results_file_name": "scitranslmed.abm7853_data_file_s1.xlsx",
            "biospecimen_type": [
                "Peripheral Blood Mononuclear Cell (PBMC)"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination I Post-symptom onset"
            ],
            "sars_cov_2_antigen": [
                "Full Length Spike Trimer"
            ],
            "assay_use": "",
            "manufacture": "components from multiple manufacturers",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID35040666_human_subject-04",
                "PMID35040666_organism_subject-05",
                "PMID35040666_organism_subject-06",
                "PMID35040666_organism_subject-07",
                "PMID35040666_organism_subject-08",
                "PMID35040666_organism_subject-09"
            ],
            "associated_first_planned_visit_id": [
                "PMID35040666_visit-03"
            ],
            "assay_type": "Other",
            "experiment_name": "in vivo lung inflammation",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Bronchoalveolar lavage I Plasma"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "Receptor Binding Domain (RBD) I Full Length Spike Trimer"
            ],
            "assay_use": "",
            "manufacture": "components from multiple manufacturers",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "",
            "assay_reporting_format": ""
        }
    ],
    "geriatric_subjects": "Yes",
    "pediatric_subjects": "No",
    "pregnant_subjects": "Not Specified",
    "sars_cov_2_antibodies_measured": "Yes",
    "survey_instrument_shared": "Not Specified",
    "who_disease_severity_scale_used": "Not Specified",
    "inclusion_exclusion": [
        {
            "inclusion_exculusion_id": "PMID35040666_inexcl-01",
            "inclusion_criterion": "Geriatric subjects",
            "inclusion_criterion_category": "inclusion"
        },
        {
            "inclusion_exculusion_id": "PMID35040666_inexcl-02",
            "inclusion_criterion": "Pediatric subjects",
            "inclusion_criterion_category": "exclusion"
        },
        {
            "inclusion_exculusion_id": "PMID35040666_inexcl-03",
            "inclusion_criterion": "SARS-CoV-2 Antibodies Measured",
            "inclusion_criterion_category": "inclusion"
        },
        {
            "inclusion_exculusion_id": "PMID35040666_inexcl-04",
            "inclusion_criterion": "Vaccine receipents",
            "inclusion_criterion_category": "inclusion"
        }
    ]
}
